Labeling and Induced Infringement in Pharma Patent Litigation and Protecting IP Rights
A live 90-minute premium CLE video webinar with interactive Q&A
This CLE course will guide patent counsel on the implications of recent litigation strategies and discuss strategic considerations of label language.
- Implications of recent decisions for induced infringement
- Other Federal Circuit induced infringement decisions
- Strategic considerations of label language for induced infringement, including applying the teachings of Sanofi and Vanda
The panel will review these and other noteworthy issues:
- What impact will recent decisions have on proving induced infringement?
- What impact will recent decisions have on claim drafting?
- What strategic considerations should patent owners keep in mind when labeling drugs?
Patricia A. Carson, Ph.D.
Kirkland & Ellis
Dr. Carson has established a reputation as a top litigator in the life sciences field. While she focuses her practice... | Read More
Dr. Carson has established a reputation as a top litigator in the life sciences field. While she focuses her practice on patent litigation including jury and bench trials, she also has extensive experience counseling clients on patenting strategy, patenting evaluation, and IP due diligence relating to transactions, including licensing, joint ventures, and acquisitions. She has represented clients in the pharmaceutical, biotechnology, chemical, medical device, consumer health care, consumer electronics, and semiconductor fields. She has a scientific background and experience as a patent examiner. She holds a Ph.D. in microbiology and immunology from Temple University School of Medicine. She devoted several years to postdoctoral studies at the Medical College of Virginia and the National Institutes of Health. She also spent several years in the U.S. Patent and Trademark Office as a patent examiner in the biotechnology group.Close
Shana K. Cyr, Ph.D., Esq.
Senior Corporate Counsel – IP
Bristol Myers Squibb
Dr. Cyr is Senior Corporate Counsel in the BD and Commercial IP Group of the Innovation Law Department at Bristol Myers... | Read More
Dr. Cyr is Senior Corporate Counsel in the BD and Commercial IP Group of the Innovation Law Department at Bristol Myers Squibb in Princeton, New Jersey. Before joining BMS, she was a partner at one of the world’s largest intellectual property law firms, focusing on complex patent litigations and contentious patent office proceedings relating to pharmaceutical products. Dr. Cyr served as judicial law clerk to the Honorable Kimberly A. Moore at the U.S. Court of Appeals for the Federal Circuit and as judicial intern to the Honorable Noel Hillman at the U.S. District Court for the District of New Jersey. Dr. Cyr holds a J.D. with High Honors from Rutgers University School of Law – Camden, a Ph.D. in chemistry from the University of Virginia, and a B.S. in chemistry with biology and mathematics minors from the University of Richmond.Close
Ms. Hooson is director in the Intellectual Property Group at Merck in Rahway, NJ. Her present responsibilities include... | Read More
Ms. Hooson is director in the Intellectual Property Group at Merck in Rahway, NJ. Her present responsibilities include patent preparation, prosecution, and due diligence support for small molecule, vaccine, and antibody programs in human and animal health. She gained her initial legal patent experience while working at GlaxoSmithKline (GSK). She received her bachelor’s degree in Biomedical Engineering from Georgia Institute of Technology, and her J.D. from Delaware Law School - Widener University. She gained considerable bio-pharmaceutical research and development and vaccine process development experience while working as an engineer at Merck, GSK, and MedImmune.Close
Sterne, Kessler, Goldstein & Fox
Ms. Vira is a director in the firm's Trial & Appellate and Biotechnology & Chemical Practice Groups. She... | Read More
Ms. Vira is a director in the firm's Trial & Appellate and Biotechnology & Chemical Practice Groups. She represents clients in complex patent litigations in federal district courts, in contested proceedings before the Patent Trial and Appeal Board, and before the Federal Circuit on appeal. She litigates cases involving a broad range of technologies in the pharmaceutical, biotechnological, and electrical arts. She focuses her practice on litigating cases involving small-molecule pharmaceuticals under the Hatch-Waxman Act and biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).Close